Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIQE Regulatory News (IQE)

Share Price Information for IQE (IQE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 28.10
Bid: 27.75
Ask: 27.85
Change: -0.65 (-2.26%)
Spread: 0.10 (0.36%)
Open: 28.60
High: 28.60
Low: 27.60
Prev. Close: 28.75
IQE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IQE plc: Trading Update

24 Nov 2021 07:00

IQE plc: Trading Update

IQE plc

Cardiff, UK24 November 2021

Trading Update

Emerging softness in smartphone-related demandContinued weakness in roll out of 5G infrastructureOngoing foreign exchange headwinds on reported numbersConstant currency revenues now anticipated to be down by circa 8% year-on-year

IQE plc (AIM: IQE, "IQE" or the "Group"), the leading supplier of compound semiconductor wafer products and advanced material solutions to the global semiconductor industry, announces a trading update for the year ending 31 December 2021.

Wireless Update

Demand for Wireless GaAs epi-wafers has continued to grow in H2 2021, driven by 5G penetration of the smartphone handset market and WiFi 6. Whilst growing year-on-year, GaAs volumes are below management expectations in Q4, in the context of softening demand within the broader smartphone supply chain.

Despite the challenges of supply chain constraints within the broader semiconductor industry, the solid performance of GaAs throughout 2021 has resulted in high utilisation at the Group’s Taiwan facility, where the Group is investing in eight new and refurbished tools. This includes three new Aixtron G4 reactors which are now on-site and being commissioned to support further growth in 2022.

Sales of Wireless GaN epi-wafers have continued to be weak due to end-market dynamics, including significantly lower levels of mMIMO base station deployments in Asia and the slow rate of deployments in Western markets. GaN remains an essential material for 5G infrastructure and demand is still expected to recover over the multi-year deployment cycle.

Photonics Update

Demand for VCSELs used in 3D sensing applications has remained solid throughout H2 2021 but is expected to tail off towards the end of the year in line with supply chain seasonality and general softening in smartphone supply chains.

Sales of other Photonics products are also below management expectations in Q4 due to the re-phasing of certain defence and security orders associated with large programmes into 2022 and the slower introduction of sales of new DFB products.

R&D Update

Strong progress continues to be made on research and development programmes, with significant milestones reached for long wavelength VCSELs, advanced healthcare sensing, Porous Silicon for front-end module switching and the commercialisation of GaN on Si technologies for infrastructure markets.

Operational progress

Operational progress has also been strong, with the closure of the Group’s Pennsylvania facility and associated consolidation of MBE capacity in North Carolina which is on schedule for completion by 2024.

The recently announced closure of the Singapore facility is also on track and due to be completed by mid-2022. These closures are part of the Group’s consolidation strategy and will improve production efficiency and margins in the medium to long term.

Outlook and Guidance

A significant foreign exchange headwind has been incurred in 2021 on a reported basis, caused by the relative strength of Sterling, versus the US Dollar in which the majority of IQE’s revenues are denominated.

As a result of softening demand in Q4, IQE now expects full year reported revenues to be in the region of GBP £152m. This is equivalent to circa £164m at constant currency, representing circa 8% reduction in revenues year-on-year.

The resultant reported Adjusted EBITDA is expected to be in the region of GBP £18m. This is equivalent to circa £25m at constant currency, representing an EBITDA margin of circa 15% at constant currency (FY2020 17%).

Cash capex in the year is expected to be in the range of £14m to £17m compared to the previous guidance of £20m to £30m, due to the phasing of payments for certain tool purchases into 2022. Net debt is expected to be less than £10m.

Phil Smith, Interim Executive Chairman of IQE, commented:

“Whilst it is disappointing that 5G infrastructure deployments have remained weak all year, we still expect this macro trend to provide a multi-year growth cycle for IQE. In the immediate term, broader semiconductor market shortages have softened demand in some supply chains but we believe these effects to be temporary and remain excited by the opportunities ahead.

Meanwhile IQE has made significant strategic and operational progress in 2021. This has laid strong foundations, which newly announced CEO Americo Lemos will look to capitalise on as he sets out his strategy for the future direction of the business next year.”

Contacts:

IQE plc+44 (0) 29 2083 9400Phil SmithTim PullenAmy Barlow Peel Hunt LLP (Nomad and Joint Broker)+44 (0) 20 7418 8900Edward KnightPaul GillamJames Smith Citigroup Global Markets Limited (Joint Broker)+44 (0) 20 7986 4000Christopher WrenPeter Catterall

Headland Consultancy (Financial PR) + 44 (0) 20 38054822Andy Rivett-Carnac: +44 (0) 7968 997 365Chloe Francklin: +44 (0)78 3497 4624

This announcement contains inside information for the purposes of Article 7 of the UK version of the Market Abuse Regulation (Regulation (EU) No 596/2014). The person responsible for arranging and authorising the release of this announcement is Tim Pullen, Chief Financial Officer.

Glossary

GaAsGallium Arsenide
GaNGallium Nitride
mMIMO Massive MIMO (Multiple-Input, Multiple Output)
VCSEL Vertical Cavity Surface Emitting Laser
DFBDistributed Feedback Laser

About IQE

http://iqep.com

IQE is the leading global supplier of advanced compound semiconductor wafers and materials solutions that enable a diverse range of applications across:

handset devicesglobal telecoms infrastructureconnected devices3D sensing

As a scaled global epitaxy wafer manufacturer, IQE is uniquely positioned in this market which has high barriers to entry. IQE supplies the whole market and is agnostic to the winners and losers at chip and OEM level. By leveraging the Group’s intellectual property portfolio including know-how and patents, it produces epitaxy wafers of superior quality, yield and unit economics.

IQE is headquartered in Cardiff UK, with c. 670 employees across nine manufacturing locations in the UK, US, Taiwan and Singapore, and is listed on the AIM Stock Exchange in London.

Date   Source Headline
8th Mar 20133:00 pmRNSMerger Update
8th Jan 20138:39 amRNSStatement regarding press articles
31st Jul 20123:54 pmRNSDirectorate Change
10th Apr 20125:11 pmRNSDirector Dealings
27th Mar 20122:00 pmRNSPartnership Agreement
8th Feb 20124:10 pmRNSCompletion of Placing
17th Feb 20103:56 pmRNSNominated Adviser Change of Name
7th Aug 20094:42 pmRNSHolding(s) in Company
7th Aug 20094:30 pmRNSBondholders meeting
7th Aug 20093:51 pmRNSDirector Dealing in Shares
12th Jun 20081:42 pmRNSAdditional Listing
15th Apr 20087:01 amRNSAdditional Listing
7th Apr 200812:14 pmRNSDirector/PDMR Shareholding
28th Mar 200811:52 amRNSDirector/PDMR Shareholding
19th Mar 20087:00 amRNSDirector/PDMR Shareholding
17th Mar 20081:00 pmRNSContract Win
17th Mar 20087:01 amRNSFinal Results
28th Feb 20083:27 pmRNSHolding(s) in Company
19th Feb 20088:30 amRNSNotice of Results
25th Jan 20087:00 amRNSBank Facilities
17th Jan 20087:00 amRNSTrading Update
16th Jan 200811:15 amRNSBroker Appointment
15th Jan 200812:12 pmRNSDirector/PDMR Shareholding
9th Jan 20084:26 pmRNSAdditional Listing
7th Jan 20087:00 amRNSDirector/PDMR Shareholding
4th Jan 200812:46 pmRNSHolding(s) in Company
19th Dec 20077:30 amRNSAdditional Listing
18th Dec 20073:52 pmRNSSubstrate supply contract
13th Dec 20077:01 amRNSSuccessful Qualifications
9th Nov 200710:53 amRNSDirector/PDMR Shareholding
3rd Oct 200710:41 amRNSDirector/PDMR Shareholding
1st Oct 20072:44 pmRNSAdditional Listing
28th Sep 200710:14 amRNSContract Win
28th Sep 20078:12 amRNSInvestor Presentation
4th Sep 200712:03 pmRNSDirector/PDMR Shareholding
28th Aug 20072:17 pmRNSHolding(s) in Company
24th Aug 20073:36 pmRNSHolding(s) in Company
22nd Aug 20077:01 amRNSContract Win
22nd Aug 20077:01 amRNSInterim Results
15th Aug 20077:01 amRNSIFRS Transitional Stmnt - Amd
14th Aug 20077:01 amRNSIFRS Transitional Statement
13th Aug 20071:19 pmRNSRule 26 Compliance
2nd Aug 20078:39 amRNSResearch Consortium
1st Aug 20073:52 pmRNSNotice of Results
25th Jul 20071:35 pmRNSResult of AGM
11th Jul 20078:00 amRNSHolding(s) in Company
9th Jul 20077:00 amRNSTrading Statement
18th Jun 20073:35 pmRNSHolding(s) in Company
4th Jun 20074:15 pmRNSHolding(s) in Company
29th May 20074:48 pmRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.